{"resourceType":"MedicinalProductDefinition","id":"equilidem-with-ing-and-auth","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tGenerated Narrative\n\t\t\t\t\u003c/b\u003e\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tId\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t: equilidem-with-ing-and-auth\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tIdentifier\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t: Equilidem25\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tCombined Pharmaceutical Dose Form\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t:\n\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/dosefom tablet}\"\u003e\n\t\t\t\t\ttablet\n\t\t\t\t\u003c/span\u003e\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tIndication\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u0026gt;\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tLegal Status Of Supply\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t:\n\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\"\u003e\n\t\t\t\t\tPrescription only medicine\n\t\t\t\t\u003c/span\u003e\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tclassification\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t:\n\t\t\t\t\u003cspan title\u003d\"Codes: {http://www.whocc.no/atc/example B01A}\"\u003e\n\t\t\t\t\tB01A\n\t\t\t\t\u003c/span\u003e\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cp\u003e\n\t\t\t\t\u003cb\u003e\n\t\t\t\t\tIngredients\n\t\t\t\t\u003c/b\u003e\n\t\t\t\t:\n\t\t\t\u003c/p\u003e\n\t\t\t\u003cblockquote\u003e\n\t\t\t\t\u003cp\u003e\n\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\tRole\n\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t:\n\t\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/ingredientType active}\"\u003e\n\t\t\t\t\t\tactive\n\t\t\t\t\t\u003c/span\u003e\n\t\t\t\t\u003c/p\u003e\n\t\t\t\t\u003cblockquote\u003e\n\t\t\t\t\t\u003cp\u003e\n\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\t:\n\t\t\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/substances 123456}\"\u003e\n\t\t\t\t\t\t\tEquilidonium Phosphate\n\t\t\t\t\t\t\u003c/span\u003e\n\t\t\t\t\t\u003c/p\u003e\n\t\t\t\t\t\u003ctable class\u003d\"grid\"\u003e\n\t\t\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t22 ml/1 tablet\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\t\u003c/table\u003e\n\t\t\t\t\u003c/blockquote\u003e\n\t\t\t\u003c/blockquote\u003e\n\t\t\t\u003cblockquote\u003e\n\t\t\t\t\u003cp\u003e\n\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\tRole\n\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t:\n\t\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/ingredientType excipient}\"\u003e\n\t\t\t\t\t\texcipient\n\t\t\t\t\t\u003c/span\u003e\n\t\t\t\t\u003c/p\u003e\n\t\t\t\t\u003cblockquote\u003e\n\t\t\t\t\t\u003cp\u003e\n\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\t:\n\t\t\t\t\t\t\u003cspan title\u003d\"Codes: {http://example.org.uk/fhir/substances 456789}\"\u003e\n\t\t\t\t\t\t\tCalcium Carbonate\n\t\t\t\t\t\t\u003c/span\u003e\n\t\t\t\t\t\u003c/p\u003e\n\t\t\t\t\t\u003ctable class\u003d\"grid\"\u003e\n\t\t\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\t\t3 ml/tablet\n\t\t\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\t\u003c/table\u003e\n\t\t\t\t\u003c/blockquote\u003e\n\t\t\t\u003c/blockquote\u003e\n\t\t\t\u003ch3\u003e\n\t\t\t\tNames\n\t\t\t\u003c/h3\u003e\n\t\t\t\u003ctable class\u003d\"grid\"\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t-\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\tProductName\n\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t*\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\tEquilidem 2.5 mg film-coated tablets\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\u003c/table\u003e\n\t\t\t\u003ch3\u003e\n\t\t\t\tCross References\n\t\t\t\u003c/h3\u003e\n\t\t\t\u003ctable class\u003d\"grid\"\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t-\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\tProduct\n\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t*\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\tLink to generic equivalent\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\u003c/table\u003e\n\t\t\t\u003ch3\u003e\n\t\t\t\tManufacturing Business Operations\n\t\t\t\u003c/h3\u003e\n\t\t\t\u003ctable class\u003d\"grid\"\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t-\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\u003cb\u003e\n\t\t\t\t\t\t\tManufacturer\n\t\t\t\t\t\t\u003c/b\u003e\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\t\u003ctr\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t*\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\t\u003ctd\u003e\n\t\t\t\t\t\t\u003cspan\u003e\n\t\t\t\t\t\t\tEquiliDrugCo Processing Inc.\n\t\t\t\t\t\t\u003c/span\u003e\n\t\t\t\t\t\u003c/td\u003e\n\t\t\t\t\u003c/tr\u003e\n\t\t\t\u003c/table\u003e\n\t\t\u003c/div\u003e"},"contained":[{"resourceType":"Ingredient","id":"EquilidoniumPhosphate","status":"active","for":[{"reference":"#"}],"role":{"coding":[{"system":"http://example.org.uk/fhir/ingredientType","code":"active"}]},"substance":{"code":{"concept":{"coding":[{"system":"http://example.org.uk/fhir/substances","code":"123456","display":"Equilidonium Phosphate"}]}},"strength":[{"presentationRatio":{"numerator":{"value":22,"unit":"ml","system":"http://unitsofmeasure.org","code":"mL"},"denominator":{"value":1,"unit":"tablet"}}}]}},{"resourceType":"Ingredient","id":"CalciumCarbonate","status":"active","for":[{"reference":"#"}],"role":{"coding":[{"system":"http://example.org.uk/fhir/ingredientType","code":"excipient"}]},"substance":{"code":{"concept":{"coding":[{"system":"http://example.org.uk/fhir/substances","code":"456789","display":"Calcium Carbonate"}]}},"strength":[{"presentationRatio":{"numerator":{"value":3,"unit":"ml","system":"http://unitsofmeasure.org","code":"mL"},"denominator":{"value":1,"unit":"tablet"}}}]}}],"identifier":[{"system":"http://example.org.uk/fhir/product","value":"Equilidem25"}],"combinedPharmaceuticalDoseForm":{"coding":[{"system":"http://example.org.uk/fhir/dosefom","code":"tablet"}]},"indication":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u003e\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.","legalStatusOfSupply":{"coding":[{"system":"http://example.org.uk/fhir/legalstatusofsupply","code":"POM","display":"Prescription only medicine"}]},"classification":[{"coding":[{"system":"http://www.whocc.no/atc/example","code":"B01A"}]}],"name":[{"productName":"Equilidem 2.5 mg film-coated tablets"}],"crossReference":[{"product":{"reference":{"reference":"MedicinalProductDefinition/genericEquilidonium"}}}],"operation":[{"organization":[{"display":"EquiliDrugCo Processing Inc."}]}]}